As the only identified coding variant was a neutral missense mutation, our results indicate that XRCC2 is not a major breast cancer susceptibility gene, in line with the studies by Hilbers et al. and Golmard et al. In contrast to XRCC2, no truncating mutations in XRCC3 or RAD51 genes have been reported and only one possibly disease-associated missense in each gene has been detected in breast cancer patients (Golmard et al. 2013; Kato et al. 2000). The gene discussed is XRCC2; the disease is breast carcinoma.